Zobrazeno 1 - 10
of 108
pro vyhledávání: ''
Autor:
Diana Abbott, Clayton A. Smith, Julie Rosser, Mohd Minhajuddin, Maria L. Amaya, Jeffrey Schowinsky, Daniel A. Pollyea, Anagha Inguva, Craig T. Jordan, Amanda Winters, Christine McMahon, Jonathan A. Gutman, Audrey Sato, Evan Cherry, Marc Schwartz, Shanshan Pei, Brett M. Stevens
Publikováno v:
Blood Advances
Key Points Patients with AML who received IC were compared with those who received ven to investigate predictors of outcomes.Presence of RUNX1 mutations is associated with better outcomes for ven/aza compared with IC.
Visual Abstract
Veneto
Visual Abstract
Veneto
Autor:
P. Andrew Futreal, Ken Furudate, Marina Konopleva, Sanam Loghavi, Guillermo Garcia-Manero, Sa A. Wang, Yuya Sasaki, Gheath Alatrash, Musa Yilmaz, Koji Sasaki, Naveen Pemmaraju, Latasha Little, Tapan M. Kadia, Koichi Takahashi, Farhad Ravandi, Kiyomi Morita, Curtis Gumbs, Jairo Matthews, Feng Wang, Hagop M. Kantarjian, Courtney D. DiNardo, Richard E. Champlin, Naval Daver, Tomoyuki Tanaka
Publikováno v:
Blood
Introduction While clonal hematopoiesis (CH) can precede the development of AML, preleukemic CH can persist after attaining remission. In rare cases, non-leukemic CH can also emerge after remission. Long-term clonal dynamics of persistent CH or emerg
Autor:
Su Young Kim, Ruby Nandam, Brenda Chyla, Shuo Ma, John Pesko, John F. Seymour, Ahmed Salem, Amanda Jacobson, Michael Y. Choi, Thomas J. Kipps, Andrew W. Roberts, Abdullah A. Masud, Mary Ann Anderson, Jennifer Arzt, Danielle M. Brander, Kathryn Humphrey
Publikováno v:
Blood
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (2
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Johan Maertens, Annoek E.C. Broers, Yvette van Norden, Mojca Jongen-Lavrencic, Gert J. Ossenkoppele, Michel van Gelder, Jan J. Cornelissen, Wendelien Zeijlemaker, Burak Kalin, Ellen Meijer, Dimitri Breems, Eric Braakman, Tim Grob
Publikováno v:
BLOOD ADVANCES, 4(18), 4430-4437. American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of e
Autor:
Bianca Rocca, Francesca Palandri, Giovanna Petrucci, Chiara Paoli, Cristina Bucelli, Benedetta Porro, Nicola Vianelli, Francesco Rodeghiero, Elena Rossi, Alessandra Iurlo, Carlo Patrono, Irene Bertozzi, Alessandro M. Vannucchi, Maria Luigia Randi, Andrea Timillero, Monica Carpenedo, Mauro Di Ianni, Giuseppe Carli, Alfredo Dragani, Silvia Betti, Denise Soldati, Elena Maria Elli, Eloise Beggiato, Valerio De Stefano, Daniele Cattaneo, Giuseppe Lanzarone, Alberto Tosetto, Viviana Cavalca, Marco Ruggeri, Giorgina Specchia, Alessandra Ricco, Paola Ranalli
Publikováno v:
Blood. 136:171-182
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet
Autor:
Oludamilola Olajide, Allison M. Deal, Nilanjan Ghosh, Jeanne F. Noe, Stephen M. Ansell, Thomas C. Shea, Nishitha Reddy, Steven I. Park, Lihua E. Budde
Publikováno v:
Blood Adv
Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment–related complications. New treatment paradigms are needed to
Autor:
Christoffer Flensburg, Piers Blombery, David C.S. Huang, Huaxian Ma, Giovanna Pomilio, Sarah MacRaild, Sanam Loghavi, Rachel Thijssen, Fiona C. Brown, Ian J. Majewski, Jessica M. Salmon, Ing Soo Tiong, Hagop M. Kantarjian, Adam Ivey, Xufeng Chen, Keyur P. Patel, Ioannis Aifantis, A. Quaglieri, Shaun Fleming, Courtney D. DiNardo, Zhen Xu, Andrew W. Roberts, Marina Konopleva, Nik Cummings, Qi Zhang, Andrew H. Wei, Steve Kornblau, Chong Chyn Chua, Christina Glytsou
Publikováno v:
Blood. 135:791-803
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based com
Autor:
Sanjeet Dadwal, Jianying Zhang, David S. Snyder, Matthew Mei, Stephen J. Forman, Haris Ali, Karamjeet S. Sandhu, Bernard Tegtmeier, Ahmed Aribi, Vinod Pullarkat, Samer K. Khaled, Amandeep Salhotra, Monzr M. Al Malki, Shukaib Arslan, Ibrahim Aldoss, Anthony S. Stein, Guido Marcucci, Ryotaro Nakamura
Publikováno v:
Blood Advances. 3:4043-4049
The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML). Treatment with VEN-HMAs results in prolonged cytopenia, thereby exposing pat
Autor:
Elisabet E. Manasanch, Surbhi Sidana
Publikováno v:
Hematology Am Soc Hematol Educ Program
You are evaluating a 47-year-old man with revised international staging system stage III myeloma who recently underwent an autologous stem cell transplant after receiving 6 cycles of carfilzomib, lenalidomide, and dexamethasone for newly diagnosed di